

Your research
has the potential
to change lives.

Let's work
together
to unlock it.

Specialized in life sciences

Founded in 2001 as a 100% subsidiary of the LifeScience Foundation for the Promotion of Science and Research, Ascenion today supports 28 research organizations across Germany in all aspects of technology transfer. Ascenion's partners include life-science institutions of the Helmholtz and Leibniz Associations, university hospitals and research centres. 10 of these endow to the LifeScience Foundation.



Adding value to our partners' projects

We work closely with our partners' scientific and administrative staff to

- identify promising research results and ideas and secure appropriate intellectual property protection,
- develop projects to attain technology readiness levels that are attractive to investors and industry and,
- market and commercialize projects through licensing, cooperations and spin-offs.

Focused on social impact

Our shared goal is to maximize the social and economic benefit of life-science research by bringing companies, services and products to market that have the potential to change our lives: for instance, new cancer treatments, environmentally friendly processes or innovative imaging techniques.

Beyond this, we usually remain involved to monitor contract compliance, support spin-off growth and manage equity. Moreover, we create dedicated funding instruments, marketing platforms, and networking events for our partners.



Tap the potential of a specialized, industry-experienced team

- Improve your technology transfer efficiency by drawing on the expertise of our multidisciplinary team, which includes analysts, lawyers, project developers and management consultants, many of them with life-science backgrounds and industry experience.
- Gain the support you need to structure multi-player deals, manage equity or develop life-science projects to industry standards.
- Find the right partners, be they life-science investors, co-developers or licensees from industry, consortia partners for federally or EU-funded projects, or dedicated experts.

Maximize the rewards from technology transfer

- Improve your organization's yield of beneficial products, services and spin-offs.
- Enhance your prospects of attracting public and private funding.
- Benefit from our strong performance and harvest the returns from deals with industry and successful spin-offs.
- Endow to the LifeScience Foundation and participate in our surplus profits.

Valuable products and jobs in growth sector

Several products and spin-offs based on our partners' research results have already reached the market, with many more on the way. Most recent successes are:

- BLINCYTO®, a new cancer drug (Max Delbrück Center for Molecular Medicine)
- VONVENDI [von Willebrand factor (Recombinant)], treatment of bleeding disorder (Max Delbrück Center for Molecular Medicine)
- Akita®, a smart inhalation device (Helmholtz Zentrum München)
- Diagnostic test for the detection of JC Virus (Deutsches Primatenzentrum)
- Trianta Immunotherapies, spin-off acquired by Medigene: development of immunotherapies for the treatment of cancer (Helmholtz Zentrum München)

Returns for public research

As a wholly-owned subsidiary of the LifeScience Foundation for the Promotion of Science and Research, Ascenion acts on behalf of inventors, their institutes, and the society. The proceeds from commercialization and other revenues generated by Ascenion are reinvested in publicly funded research.



Close to our partners

With offices in Munich, Neuherberg, Berlin, Braunschweig, Hamburg and Hanover, our technology managers stay in close contact with the staff at our partner institutes.

Ascenion GmbH
Herzogstraße 64
80803 Munich, Germany

T +49 89 318814-0

info@ascenion.de
www.ascenion.de

Ascenion at a Glance

